Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases

MLA

D. V. Bukhanova, et al. “Efficacy, Safety and Immunogenicity of a Trivalent Inactivated Split Influenza Vaccine in Patients with Rheumatic Diseases.” Медицинский Совет, no. 12, July 2018, pp. 106–10. EBSCOhost, https://doi.org/10.21518/2079-701X-2018-12-106-110.

APA

D. V. Bukhanova, B. S. Belov, G. M. Tarasova, Sh. Erdes, T. V. Dubinina, G. V. Lukina, N. V. Demidova, A. V. Volkov, N. N. Yudkina, M. V. Cherkasova, & M. E. Diatroptov. (2018). Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases. Медицинский Совет, 12, 106–110. https://doi.org/10.21518/2079-701X-2018-12-106-110

Chicago

D. V. Bukhanova, B. S. Belov, G. M. Tarasova, Sh. Erdes, T. V. Dubinina, G. V. Lukina, N. V. Demidova, et al. 2018. “Efficacy, Safety and Immunogenicity of a Trivalent Inactivated Split Influenza Vaccine in Patients with Rheumatic Diseases.” Медицинский Совет, no. 12 (July): 106–10. doi:10.21518/2079-701X-2018-12-106-110.